ライフサイエンスコーパス: phenobarbital

1 ent tumours generated by the tumour promoter phenobarbital.

2 in levels can be decreased by treatment with phenobarbital.

3 in potentiating the anticonvulsant effect of phenobarbital.

4 mine, barbiturates, propofol, pentobarbital, phenobarbital.

5 cess in parental reports of side-effects for phenobarbital.

6 d not affect the EC50 of chlordiazepoxide or phenobarbital.

7 7 bl/6 mice by either beta-naphthoflavone or phenobarbital.

8 t increased by treatment of the animals with phenobarbital.

9 dose of opioid were treated with adjunctive phenobarbital.

10 idely used GABAergic anticonvulsants such as phenobarbital.

11 ime, but not by the indirect hCAR activator, phenobarbital.

12 he day they were given an overdose of sodium phenobarbital.

13 d 32 mg, respectively; 17% were treated with phenobarbital.

14 HNF-4alpha mRNA is modestly up-regulated by phenobarbital.

15 N62 block nuclear induction of HNF-4alpha by phenobarbital.

16 clear expression is regulated in response to phenobarbital.

17 n after administration of ethanol, MK801, or phenobarbital.

18 ldren were randomly allocated treatment with phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance

19 men were randomly assigned to receive either phenobarbital (10 mg per kilogram of body weight) or pla

20 kilogram), lorazepam (0.1 mg per kilogram), phenobarbital (15 mg per kilogram), and phenytoin (18 mg

21 using hepatocytes treated for 48 hours with phenobarbital (2 mmol/L), oltipraz (50 micromol/L), or 3

22 In children with cerebral malaria, phenobarbital 20 mg/kg provides highly effective seizure

23 omly assigned a single intramuscular dose of phenobarbital (20 mg/kg) or identical placebo.

24 of the synaptic-dependent antiepileptic drug phenobarbital (20-40 microM) failed to inhibit veratridi

25 in 13 of the 30 neonates assigned to receive phenobarbital (43 percent) and 13 of the 29 neonates ass

26 In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation

27 inducing AED (carbamazepine, phenytoin, and phenobarbital), a cP450 inhibiting AED (valproate), or a

28 Phenobarbital administration did not interfere with the

29 The results indicate that phenobarbital alleviates the malfunction of the mutated

30 We report that a barbiturate anticonvulsant, phenobarbital, alleviates the effect of this mutation.

31 In contrast, induction of MRP2 by phenobarbital, an activator of CAR, was comparable in wi

32 ogenesis were rescued with administration of phenobarbital, an enhancer of GABA(A) receptor activity.

33 e and treated the resulting animals with DEN/Phenobarbital, an established protocol for liver carcino

34 Of the remaining 340, 170 received phenobarbital and 170 placebo.

35 ncentrations of 25 microg per milliliter for phenobarbital and 3 microg per milliliter for phenytoin.

36 esponse to GABAergic anticonvulsants such as phenobarbital and benzodiazepines.

37 ress this issue, cirrhosis was induced using phenobarbital and carbon tetrachloride (CCL(4)) and anim

38 Liver cirrhosis was induced with phenobarbital and carbon tetrachloride.

39 In the flurothyl model, phenobarbital and diazepam increased latency to seizure

40 er of two commonly used antiepileptic drugs, phenobarbital and diazepam, in preventing and suppressin

41 rtine, a selective KCNQ channel opener, with phenobarbital and diazepam, two drugs in current use for

42 Here we show that phenobarbital and dizocilpine can block measures of METH

43 Phenobarbital and dizocilpine did not block depletions b

44 logical studies found an association between phenobarbital and hepatocellular carcinoma, and several

45 nal injury, we found that the GABAA agonists phenobarbital and midazolam significantly increased stat

46 Phenobarbital and MK-801 were superior to phenytoin in s

47 e allocated to receive an additional dose of phenobarbital and one of four bumetanide dose levels by

48 Phenobarbital and phenytoin are equally but incompletely

49 ain, there may also be risks associated with phenobarbital and phenytoin exposure.

50 les did not differ significantly between the phenobarbital and phenytoin groups (Conners 2.64 [SD 0.7

51 We undertook a randomised comparison of phenobarbital and phenytoin to assess the acceptability

52 methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to

53 been seen unequivocally in rodent models for phenobarbital and phenytoin; phenobarbital promoted live

54 nes respond to prototypical inducers such as phenobarbital and rifampicin, yet little has been report

55 with the nonselective potentiating compounds phenobarbital and tracazolate.

56 with corn oil (CO) or inducers of CYP2B (PB; phenobarbital) and CYP3A enzymes (DX; dexamethasone), is

57 pression of CYP2B6 induced by both indirect (phenobarbital) and direct CITCO [6-(4-chlorophenyl)imida

58 naphthalic anhydride (NA), triasulfuron (T), phenobarbital, and bacterial pathogens (Erwinia stuartii

59 UGT1A transcriptional activation by dioxin, phenobarbital, and endotoxin was significantly reduced i

60 d-generation AEDs, carbamazepine, phenytoin, phenobarbital, and primidone are potent inducers of hepa

61 d generation AEDs, carbamazepine, phenytoin, phenobarbital, and primidone induce the activity of seve

62 prim, triamterene, carbamazepine, phenytoin, phenobarbital, and primidone, may increase the risk not

63 nts who required supplemental treatment with phenobarbital, and safety.

64 metabolism, the rodent liver tumor promoter phenobarbital, and the skin tumor promoters okadaic acid

65 traditional antiepileptic agents phenytoin, phenobarbital, and valproate.

66 zed ultrafiltration of affinity complexes of phenobarbital antibody and barbiturates, including the s

67 Benzodiazepines are a reasonable option; phenobarbital appears to confer some advantages in combi

68 , pentobarbital ( approximately 310 microM), phenobarbital ( approximately 1.54 mM)] similar to that

69 This evidence supports the acceptability of phenobarbital as a first-line drug for childhood epileps

70 to assess the acceptability and efficacy of phenobarbital as monotherapy for childhood epilepsy in r

71 These results are consistent with phenobarbital-associated impairment of canalicular egres

72 0 mg/kg dose, CYP2B1 and CYP2B2 induction by phenobarbital at 1 mg/kg was unaffected by age or gender

73 ith the S9 fraction of liver homogenate from phenobarbital/beta-naphthoflavone-induced Sprague-Dawley

74 onal degeneration since co-administration of phenobarbital blocked cell death.

75 The anticonvulsant efficacy of phenobarbital, bumetanide, and the combination of these

76 binding to microsomes from rats treated with phenobarbital but had no effect on microsomes from untre

77 d CncC binding at these loci was enhanced by phenobarbital, but not by tert-butylhydroquinone (tBHQ)

78 s or longer with anticonvulsants (phenytoin, phenobarbital, carbamazepine, or a combination) at the s

79 in plasma concentrations of lamotrigine and phenobarbital caused by valproic acid.

80 Phenobarbital changes the channel-opening rate constant

81 lly interfering drugs such as metronidazole, phenobarbital, chlorpheniramine maleate, pyridoxine and

82 tment with many drugs, including rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole.

83 In conclusion, the phenobarbital/cocaine injury model is useful to study re

84 Plasma phenobarbital concentrations were measured.

85 atment of these mice with diethylnitrosamine/phenobarbital (DEN/PB), which induces formation of liver

86 demonstrated that the classic CAR activator phenobarbital dephosphorylates the corresponding threoni

87 f primary cultures of human hepatocytes with phenobarbital, dexamethasone, or rifampin elevated hepat

88 Antenatal administration of phenobarbital does not decrease the risk of intracranial

89 ings suggest that bumetanide as an add-on to phenobarbital does not improve seizure control in newbor

90 curred in Pbp(DeltaLiv) mice pretreated with phenobarbital due to lack of expression of xenobiotic me

91 eptic drugs ethosuximide (ED50 = 161 mg/kg), phenobarbital (ED50 = 22 mg/kg), and valproic acid (ED50

92 ency of seizure-like events and reduction in phenobarbital efficacy.

93 levations that were approximately 25-100% of phenobarbital-elicited increases) of CYP2B mRNA and immu

94 ate, males and females neonatally exposed to phenobarbital exhibited a dramatic overinduction of mult

95 Phenobarbital-exposed rats were also assessed for revers

96 Additionally, phenobarbital exposure impaired striatal-mediated behavi

97 bination of these drugs was studied RESULTS: Phenobarbital failed to abolish or depress recurrent sei

98 ponse to periportal liver injury, induced by phenobarbital feeding and cocaine injection, is used to

99 percent) of the neonates assigned to receive phenobarbital first and 18 (62 percent) of those assigne

100 iated with diethylnitrosamine, maintained on phenobarbital for 6 months after weaning, and then subje

101 The use of phenobarbital for childhood epilepsy is controversial be

102 ty of intravenous bumetanide as an add-on to phenobarbital for treatment of neonatal seizures.

103 seizures not responding to a loading-dose of phenobarbital from eight neonatal intensive care units a

104 Partition coefficients for phenobarbital (from aqueous solution to membrane) decrea

105 ge was diagnosed in 70 of 311 infants in the phenobarbital group (23 percent) and 64 of 279 in the pl

106 of the 344 infants born to the women in the phenobarbital group (24 percent) and in 74 of the 324 bo

107 A total of 247 women (80 percent) in the phenobarbital group and 235 (78 percent) in the placebo

108 There were 309 women in the phenobarbital group and 301 in the placebo group.

109 ure frequency was significantly lower in the phenobarbital group than in the placebo group (18 [11%]

110 ency of respiratory arrest was higher in the phenobarbital group than in the placebo group, and morta

111 3 percent; risk ratio for the infants in the phenobarbital group, 1.1; 95 percent confidence interval

112 Phenobarbital had insignificant anticonvulsant responses

113 treated with human hepatocyte cell therapy, phenobarbital has been used for reducing the serum bilir

114 n vivo drug metabolism was more rapid in the phenobarbital-imprinted male and female animals.

115 4.9 percent of those assigned to receive it, phenobarbital in 58.2 percent, diazepam plus phenytoin i

116 . -susceptible strains and can be induced by phenobarbital in adult susceptible flies.

117 In contrast, phenobarbital in combination with bumetanide abolished s

118 etanide enables the anticonvulsant action of phenobarbital in immature brain.

119 The efficacy of phenobarbital in potentiating currents elicited by a sat

120 tudy to assess the efficacy of intramuscular phenobarbital in preventing seizures in childhood cerebr

121 Diffusion coefficients of the solute phenobarbital in receptor-free membranes were also deter

122 tanide enhances the anticonvulsant action of phenobarbital in the neonatal brain METHODS: Recurrent s

123 elevated 3 hours after the administration of phenobarbital in wild-type, CAR-/-, and CAR-/-/PXR-/- mi

124 signs (and their alleviation by diazepam and phenobarbital) in mice are similar to those of the class

125 ate formation constants of a target species, phenobarbital, in membranes with various polymer concent

126 characterized nongenotoxic hepatocarcinogen, phenobarbital, in rats.

127 Phenobarbital increases Cyp2B expression in liver via ac

128 ingle i.v. dose of Alas1-siRNA prevented the phenobarbital-induced biochemical acute attacks for appr

129 We showed previously that phenobarbital-induced CYP2B protein is down-regulated in

130 ssociated protein (GAP)-43/neuromodulin, and phenobarbital-induced cytochrome P450.

131 entiated hepatocytes, and in rifampicin- and phenobarbital-induced hepatocytes.

132 In vitro analysis revealed that phenobarbital-induced HNF-4alpha expression is both time

133 mg/kg/day that were approximately 32-87% of phenobarbital-induced increases.

134 DNA clone designated 2B2FF was obtained from phenobarbital-induced Lewis rats and, like some previous

135 zyme gave products similar to those from the phenobarbital-induced microsomes.

136 liver microsomal P450 cytochromes, including phenobarbital-induced P450 2B4, catalyze the analogous d

137 -H abstraction and/or a SET mechanism, using phenobarbital-induced rat liver microsomal P450 enzymes

138 n nuclear extracts prepared from control and phenobarbital-induced rat livers.

139 cosa-5,8,11-trienoic acid in microsomes from phenobarbital-induced rats.

140 ranscripts in older seedling shoots, whereas phenobarbital induces CYP92A1 expression in older seedli

141 hyde dehydrogenase, but is distinct from rat phenobarbital-inducible aldehyde dehydrogenase (PIADH),

142 aracterized as a trans-acting factor for the phenobarbital-inducible Cyp2b10 gene.

143 tocytes: they secreted urea and albumin, had phenobarbital-inducible cytochrome p450, could take up L

144 a dose-dependent increase in UGT2B1 mRNA, a phenobarbital-inducible enzyme; mRNA levels reached 210

145 mechanisms of mitochondrial targeting of the phenobarbital-inducible hepatic mitochondrial P450MT4, w

146 ALDHs): a constitutive isozyme (ALDH1) and a phenobarbital-inducible isozyme (ALDH-PB).

147 The phenobarbital-inducible rat cytochrome P450 (CYP) 2B1 an

148 ion studies and consistent with mediation of phenobarbital induction by CAR.

149 reased by NF-1, analogous to NF-1 effects on phenobarbital induction in previous transient transfecti

150 Phenobarbital induction of CYP2B genes is mediated by a

151 an additional inhibitory signal antagonizing phenobarbital induction of CYP2B1 and CYP2B2.

152 Phenobarbital induction of transcription of CYP2B genes

153 To further delineate the mechanism of phenobarbital induction, protein binding in native chrom

154 trienoic acid, and the amounts increase upon phenobarbital induction.

155 lt males exhibiting the least suppression of phenobarbital induction.

156 Phenobarbital is a classical inducer of the drug metabol

157 Phenobarbital is a lipophilic molecule used as a sedativ

158 res, as early life exposure to drugs such as phenobarbital is associated with adverse neurological ou

159 ric acid (GABA) neurotransmitter receptor by phenobarbital is presented.

160 CPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.

161 TSO is considered a phenobarbital-like compound because it induces Cyp2B mRN

162 city in wild-type mice previously exposed to phenobarbital-like inducers and this toxicity is also ab

163 oked by a class of xenobiotics known as the 'phenobarbital-like inducers'.

164 not consistent with the previously described phenobarbital-like properties of tamoxifen and could be

165 scued by mevalonate supplementation, whereas phenobarbital-mediated induction was unaffected by these

166 Phenobarbital, MK-801, and phenytoin were administered a

167 romol/L) revealed UGT1A1-inducing effects of phenobarbital, oltipraz, and, in particular, 3-methylcho

168 We studied the effects of phenobarbital on HNF-4alpha expression in hepatocytes an

169 ed the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial

170 animals were pretreated with CAR activators, phenobarbital or 1,4-bis[2-(3,5-dichlorpyridyloxy)]benze

171 ctra using microsomes from rats treated with phenobarbital or dexamethasone but not from untreated ra

172 though lorazepam is no more efficacious than phenobarbital or diazepam plus phenytoin, it is easier t

173 Unlike phenobarbital or diazepam, flupirtine prevented animals

174 Phenobarbital or dizocilpine during METH exposure blocke

175 We found therapeutic intervention with phenobarbital or phenytoin ineffective, whereas interven

176 tes were randomly assigned to receive either phenobarbital or phenytoin intravenously, at doses suffi

177 The treatment is usually with either phenobarbital or phenytoin, but the efficacy of the two

178 Treatment of mice with phenobarbital or TCPOBOP resulted in decreased hepatic m

179 nsferase alpha), following pretreatment with phenobarbital or TCPOBOP.

180 id, and calcium ionophore A23187, but not by phenobarbital or the steroid PP dehydroepiandrosterone s

181 Administration of diethylnitrosamine, phenobarbital, or 2-amino-3,8-diethylimidazo[4,5-f]quino

182 ong activation of Cyp2b10 gene expression by phenobarbital, or by the more potent TCPOBOP, is absent

183 on-cholinergic drugs, diazepam, haloperidol, phenobarbital, pargyline, D-amphetamine, imipramine, pir

184 Phenobarbital (PB) administration is known to trigger pl

185 nstitutive androstane receptor (CAR) ligands phenobarbital (PB) and 1,4-bis-[2-(3,5-dichloropyridylox

186 by therapeutic drugs and xenobiotics such as phenobarbital (PB) and 1,4-Bis[2-(3,5-dichloropyridyloxy

187 In response to phenobarbital (PB) and other PB-type inducers, the nucle

188 observed after pretreatment of animals with phenobarbital (PB) and pregnenolone-16alpha-carbonitrile

189 atomegaly induced by the xenobiotic mitogens phenobarbital (PB) and TCPOBOP (1, 4-bis [2-(3, 5-dichlo

190 samine (DEN) and continued administration of phenobarbital (PB) in drinking water.

191 DDE is similar to phenobarbital (PB) in that both compounds are inducers o

192 xtracts against diethylnitrosamine (DEN) and phenobarbital (PB) induced hepatic injury in rats.

193 Phenobarbital (PB) induces various gene encoding drug/st

194 The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG

195 Phenobarbital (PB) induction of CYP2B genes is mediated

196 specific receptors thought to be involved in phenobarbital (PB) induction, the constitutive androstan

197 tein synthesis is a critical requirement for phenobarbital (PB) induction.

198 Phenobarbital (PB) is a prototype for a class of agents

199 Phenobarbital (PB) is an archetypal representative for c

200 Phenobarbital (PB) is the prototype of nongenotoxic caci

201 CC in response to a Diethylnitrosamine (DEN)/Phenobarbital (PB) liver tumor-induction protocol.

202 ma C6 cells were treated with P-450 inducers phenobarbital (PB) or benzo[a]anthracene (BA).

203 For decades, phenobarbital (PB) treatment for hyperbilirubinemia has

204 Phenobarbital (PB) treatment impairs the biliary excreti

205 r (CAR) translocates into liver nuclei after phenobarbital (PB) treatment, and activates the conserve

206 , such as P4502B, are known to be induced by phenobarbital (PB), and these P450s share a consensus se

207 typical P450 inducers (beta-naphthoflavone, phenobarbital (PB), Aroclor 1254, isoniazid, pregnenolon

208 Induction of P450s by phenobarbital (PB), beta-naphthoflavone (betaNF), or clo

209 eceptor signals xenobiotic exposure, such as phenobarbital (PB), by translocating into the nucleus.

210 nal responses to three xenobiotic compounds: phenobarbital (PB), chlorpromazine, and caffeine.

211 rat brain capillaries to the CAR activator, phenobarbital (PB), increased the transport activity and

212 en for this study were microcystin-LR (MLR), phenobarbital (PB), lipopolysaccharide (LPS), carbon tet

213 eritoneal [i.p.]) was administered to naive, phenobarbital (PB)-induced or beta-naphthoflavone (betaN

214 The mouse phenobarbital (PB)-inducible Cyp2b10 gene promoter has b

215 AR) is a key transcription factor regulating phenobarbital (PB)-inducible transcription of various he

216 global hepatic protein synthesis, including phenobarbital (PB)-mediated induction of CYP2B enzymes i

217 have identified key candidate regulators of phenobarbital (PB)-mediated mouse liver tumorigenesis, a

218 tion rate is increased using microsomes from phenobarbital (PB)-pretreated rats.

219 nd diethylnitrosamine (DEN)-initiated and/or phenobarbital (Pb)-promoted HCC development using HCV co

220 By extending previous studies of the phenobarbital (PB)-responsive 132-base pair (bp) enhance

221 transactivates a distal enhancer called the phenobarbital (PB)-responsive enhancer module (PBREM) fo

222 or the induction of cytochrome P450 genes by phenobarbital (PB).

223 sed by treatment with certain drugs, such as phenobarbital (PB).

224 o the rodent liver non-genotoxic carcinogen, phenobarbital (PB).

225 ntiepileptic drugs with proapoptotic action (phenobarbital, phenytoin, lamotrigine) and without proap

226 nt in rats exposed at P7 to a single dose of phenobarbital, phenytoin, or lamotrigine.

227 o exposure to FAAs (including carbamazepine, phenobarbital, phenytoin, primidone, sulfasalazine, tria

228 s greatly increased in children who received phenobarbital plus three or more doses of diazepam (odds

229 t study, we found that liver microsomes from phenobarbital pretreated rats (which contain CYP2B1 as t

230 In vivo phenobarbital pretreatment a changed V-G excretion from

231 Animals receiving phenobarbital prior to daily kindling failed to recover

232 Perinatal exposure to phenobarbital produces a range of permanent reproductive

233 dent models for phenobarbital and phenytoin; phenobarbital promoted liver tumours and phenytoin cause

234 nsgenic mice via adaptive recognition of the phenobarbital response element (PBRE).

235 NF-4alpha and CAR is an integral part of the phenobarbital response, aimed at coordinated regulation

236 resulted in identification of an ARE in the phenobarbital-response enhancer module region of the UGT

237 B genes is mediated by an enhancer, termed a phenobarbital responsive unit (PBRU), approximately 2000

238 tion of CYP2B genes is mediated by a complex phenobarbital-responsive enhancer (PBRU), which contains

239 pression of CYP2B6 reporter genes containing phenobarbital-responsive enhancer module (PBREM) or PBRE

240 XR was shown to be capable of activating the phenobarbital-responsive enhancer module (PBREM) region

241 tional regulation of CYP2B genes through the phenobarbital-responsive enhancer module (PBREM).

242 pyridyloxy)]benzene (TCPOBOP) via the distal phenobarbital-responsive enhancer module (PBREM, at -173

243 F-kappaB, CBLB502 strongly activated STAT3-, phenobarbital-responsive enhancer module (PREM), and act

244 PBREM, the phenobarbital-responsive enhancer module of the cytochro

245 6 promoter; and looping the PXR-bound distal phenobarbital-responsive enhancer module toward the prox

246 responsible for mediating induction of many phenobarbital-responsive genes.

247 region or containing a previously described phenobarbital-responsive region.

248 chromatin structure, protein binding to the phenobarbital-responsive unit assessed by in vitro DNase

249 Functional analyses have identified a phenobarbital-responsive unit in the rat CYP2B1/2 and mo

250 n or architecture of proteins binding to the phenobarbital-responsive unit region and indicate that c

251 n of DNA into rat liver may be used to assay phenobarbital responsiveness of cytochrome P450 genes.

252 oses of CCl(4) in the presence or absence of phenobarbital resulted in increased injury and fibrosis

253 Suppression of these seizures with phenobarbital reversed the change in the voltage depende

254 Phenobarbital significantly augmented the bilirubin-lowe

255 ructure of an intact monoclonal antibody for phenobarbital, subclass IgG1, has been determined to 3.2

256 Phenobarbital suppressed thalamic seizure activity.

257 e dose of bumetanide with the second dose of phenobarbital; three were withdrawn for reasons unrelate

258 administration of therapeutic-like doses of phenobarbital to male and female rat pups during the fir

259 The administration of phenobarbital to pregnant women before delivery has been

260 d, n = 14; 2) heterotopically placed grafts, phenobarbital-treated (80 mg/kg/day), n = 17; 3) orthoto

261 in binding between extracts from control and phenobarbital-treated animals.

262 Incubation of liver microsomes from phenobarbital-treated males with monospecific anti-CYP2B

263 In the phenobarbital-treated mice, the binding of both CAR and

264 exhibited a strong synergistic expression in phenobarbital-treated mice.

265 tor RXR from the hepatic nuclear extracts of phenobarbital-treated mice.

266 eceiving saline prior to kindling as well as phenobarbital-treated non-kindled animals recovered with

267 Microsomes from phenobarbital-treated rats or purified P450 2B1 catalyze

268 y liver microsomes isolated from control and phenobarbital-treated rats, and by purified cytochrome P

269 n = 5; and 4) orthotopically placed grafts, phenobarbital-treated, n = 7.

270 Phenobarbital treatment "normalized" serum bilirubin lev

271 hese results provide the first evidence that phenobarbital treatment alters the composition or archit

272 The combination of phenobarbital treatment and orthotopic small bowel trans

273 In contrast, phenobarbital treatment dramatically altered the protect

274 With mice, phenobarbital treatment elevated liver microsomal ring h

275 Phenobarbital treatment increased hyper-sensitivity in l

276 ction with dimethyl sulfate was observed and phenobarbital treatment increased the hypersensitivity b

277 Phenobarbital treatment of Gunn recipients of jejunal tr

278 Inhibition of the gonadotropin surge by phenobarbital treatment on D4:1100 h attenuated ESR36 ex

279 These data indicate that in liver phenobarbital treatment substantially alters protein bin

280 In this study, we used diethylnitrosamine/phenobarbital treatment to induce hepatocellular carcino

281 However, after phenobarbital treatment, the protection of this core reg

282 and Pepck was detected in mouse liver after phenobarbital treatment, whereas association of HNF-4 an

283 -1 and flanking NR sites were occupied after phenobarbital treatment.

284 A level after BA (benzo(a)anthracene) or PB (phenobarbital) treatments was detected.

285 mice treated with a diethylnitrosamine (DEN)/phenobarbital tumor induction protocol.

286 Sixteen structurally unrelated phenobarbital-type inducers activated the 51-bp enhancer

287 of the cytochrome P450 2B6 (CYP2B6) gene by phenobarbital-type inducers, such as 1,4 bis[2-(3,5-dich

288 -plant allelochemicals (up to 11.5-fold) and phenobarbital (up to 49-fold) corroborates previous in v

289 of diazepam (248 vs. 562 mg; p = .001), and phenobarbital use (17 vs. 58%; p = .01).

290 The odds ratio for behavioural problems (phenobarbital vs phenytoin) was 0.51 (95% CI 0.16-1.59).

291 Adjunctive phenobarbital was administered in 5 of 33 infants (15%)

292 To this end, phenobarbital was coupled with daily electrical kindling

293 Phenobarbital was most effective in suppressing electrog

294 features similar to those of the barbiturate phenobarbital were synthesized; one DHPM used (monastrol

295 Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have

296 Uncoupling increases after treatment with Phenobarbital, which enhances the GABA(A) receptor (GABA

297 Treatment with phenobarbital, which increased steady-state RcGshT mRNA

298 Phenobarbital, which is not a CAR ligand, binds the EGF

299 maleate] or the GABA(A) receptor potentiator phenobarbital, which mimics components of the effects of

300 doses of benzodiazepines in combination with phenobarbital would improve outcomes.